The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.

Leach, Martin O; Brindle, K; Evelhoch, J; Griffiths, John R; Horsman, Michael R; Jackson, A; Jayson, Gordon C; Judson, Ian R; Knopp, M; Maxwell, Ross J; McIntyre, D; Padhani, A; Price, P; Rathbone, R; Rustin, G; Tofts, P; Tozer, G; Vennart, W; Waterton, John C; Williams, S; Workman, Paul

Affiliation

Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, UK. martin.leach@icr.ac.uk

Issue Date

2005-05-09

Metadata

Show full item record

Abstract

Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.

Citation

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. 2005, 92 (9):1599-610 Br. J. Cancer

Journal

British Journal of Cancer

URI

http://hdl.handle.net/10541/74932

DOI

10.1038/sj.bjc.6602550

PubMed ID

15870830

Type

Article

Language

ISSN

0007-0920

Collections

All Christie Publications